Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
News|Articles|June 1, 2024
Psychedelics Utilization Poll
Author(s)Psychiatric Times Editors
Answer a quick question about psychedelics!
Advertisement
If approved by the FDA, would you be interested in delivering psychedelics to patients?
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
4
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
5